Topical Thrombin and Control of Wound Hæmatoma

Jasani, Bonny; Donaldson, Liam; Baxter-Smith, D. C.; Selvam, A.; Sokhi, G. S.

doi:10.1016/s0140-6736(77)91489-1

Cited by 9 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There was also interest in the use of thrombin for the treatment of burns (141) but it would appear that the use of epinephrine has supplanted thrombin in the treatment of bleeding secondary to burns (142)(143)(144)(145)(146)(147). There are also uses in other areas of surgery (148)(149)(150)(151)(152)(153)(154)(155)(156)(157)(158).…”

Section: Therapeutic Uses Of Thrombinmentioning

confidence: 99%

A review of the therapeutic uses of thrombin

Lundblad

Bradshaw

Gabriel³

et al. 2004

Thromb Haemost

View full text Add to dashboard Cite

Thrombin is the product of the hemostatic response essential to the conversion of fibrinogen to fibrin. In addition, it is also responsible for the aggregation of blood platelets in the formation of the "platelet plug" as well as the activation of factor VIII, factor V, factor XI, factor XIII and protein C. The action of thrombin is not confined to the hemostatic response as it also has a critical function in the wound healing process by stimulating 'mitogenic' events through interaction with cell surface receptors. In this review, we consider the various biological activities of thrombin as they relate to current therapeutic use. While there has been considerable interest in the development of fibrin sealant products, there has been considerably less interest in documenting the continuing use of thrombin as a therapeutic. The use of thrombin for topical hemostasis and the treatment of pseudoaneurysms will be discussed in detail. It is concluded that the use of thrombin as a drug will not only continue but also will significantly increase. However, the availability of a safe human thrombin preparation will be critical for the continued use of thrombin as a therapeutic.

show abstract

Section: Therapeutic Uses Of Thrombinmentioning

confidence: 99%

A review of the therapeutic uses of thrombin

Lundblad

Bradshaw

Gabriel³

et al. 2004

Thromb Haemost

View full text Add to dashboard Cite

show abstract

“…Thrombin has been used in surgical procedures as a means of reducing wound bleeding for decades. In 1977, Jasani reported that 15 patients treated with topical thrombin after abdominal surgery exhibited significantly fewer hematomas compared with the control group not receiving treatment (3). This finding was later confirmed by Hashemi et al, who showed that heparinized patients receiving treatment with topical thrombin had a reduced rate of hematoma formation (4).…”

mentioning

confidence: 91%

Quality of Thrombin Produced From the Patient’s Own Plasma Using the TPD™, a New Thrombin-Processing Device

Semple¹,

Madsen²,

Semple³

2005

J Extra Corpor Technol

View full text Add to dashboard Cite

Thrombin derived from bovine sources commonly is used to arrest bleeding during surgical procedures. However, complications such as postoperative hemorrhage can occur because of the development of cross-reactive anti-bovine antibodies that inhibit human coagulation factor V. It would thus be advantageous to develop techniques to generate human thrombin. This study evaluated thrombin produced from human plasma using a new Thrombin-Processing Device (TPD™). Plasma was introduced into the TPD, mixed with an ethanol/CaCl2 reagent, incubated for 1 h, and the harvested thrombin was assayed for activity and the ability to activate platelets by in vitro assays. TPD-produced thrombin activity was found to be 51.8 ± 12.4 IU/mL (n = 145). TPD-produced thrombin also stimulated P-selectin (CD62) expression (83 ± 13% of the platelet population) and Annexin V binding (10.3 ± 2% of the platelet population) on platelets in a similar fashion to commercial thrombin (P-selectin expression: 88 ± 3%; Annexin-V binding: 11.4 ± 3%). Compared with CaCl2 and batroxobin, TPDproduced thrombin had a significantly greater ability to activate platelets. TPD-produced thrombin from human plasma has consistent activity and significantly activates platelets and, thus, may have attractive applications such as the production of autologous thrombin for surgical patients.

show abstract